SPRC Market Opportunities (1)
Tourette Syndrome (TS) - $80M in 2019 and is expected to reach $98.7M by 2023.
Autism Spectrum Disorder (ASD) - The global ASD therapeutics market was approximately $3.3B in 2018 and is expected to reach approximately $4.6B by 2026.
Status Epilepticus - The global epilepsy market size would grow from $8.8B in 2018 to $9.5B towards the end of 2023.
Alzheimer’s Disease (AD) - The global Alzheimer’s therapeutics market is projected to reach $13.6B by 2027 from $7.4B in 2019.
Pain and Inflammation - The global chronic pain treatment market was valued at $77.8B in 2019.
Read more from the SPRC company presentation here.
And as I mentioned above, SPRC has several potential catalysts to know right now. Check them out:
No. 1 SPRC Potential Catalyst - A Tiny Float Could Allow Major Volatility
According to the Yahoo Finance website, SPRC has a very low float like several of my recent Nasdaq breakout ideas.
In fact, the website reports SPRC to have approximately 3.09Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility.
With so few shares available for trading, other potential catalysts could help to provide a spark towards a possible vertical move in the near-term.
No. 2 SPRC Potential Catalyst - Initial Results Come Back Positive For Co-caine Addiction Treatment
SciSparc Ltd. Announces Initial Positive Results for the Co-caine Addiction Treatment of Clearmind Medicine Inc.
SciSparc and Clearmind recently announced the filing of a patent application related to treating cocaine addiction
TEL AVIV, Israel, June 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced that initial positive pre-clinical results for treatment for co-caine addiction using MEAI, a novel psych-e-delic molecule of Clearmind Medicine Inc. (“Clearmind”) (CSE: CMND), (OTC: CMNDF), (FSE: CWY0).
Pursuant to SciSparc last announcement on June 2, 2022, whereby the Company announced the collaborated filing of a provisional patent application related to treating co-caine addiction with Clearmind based on SciSparc’s CannAmide™ compound and Clearmind’s MEAI, the pre-clinical trials show possible positive results which may positively affect our collaboration.
"We are excited about Clearmind's results, in light of the potential synergistic effect between SciSparc’s CannAmide compound and Clearmind’s MEAI, as previously demonstrated in joint studies, which reflected the dose dependency effect. We plan to continue to investigate these findings, which for the first time point to a potential treatment for co-caine addiction. Since commencing the collaboration with Clearmind, we have been able to present successful results for our proprietary combination treatment,” commented Oz Adler, SciSparc's Chief Executive Officer. "It is our intention to further investigate the effect of this treatment on different addictions and other binge behaviors."
Read the full article here.
No. 3 SPRC Potential Catalyst - A New Collaboration Could Lead To Breakthrough Pain Treatments
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
SciSparc will use its SCI-160 technology platform for treating pain in combination with Polyrizons' Trap and TargetTM technology
TEL AVIV, Israel, May 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system (the "Company" or "SciSparc"), today announced it has signed a collaboration agreement with Polyrizon Ltd., a biotech company focused on the development of innovative medical device hydrogels delivered in the form of nasal sprays (“Polyrizon”).
As part of the collaboration, the two companies will work to develop a unique technology for the treatment of pain, based on SciSparc's SCI-160 platform and Polyrizon’s Trap and TargetTM intranasal drug delivery technology to target the central nervous system.
Dr. Adi Zuloff-Shani, SciSparc's Chief Technologies Officer, commented "SciSparc’s objective to revolutionize cann-a-binoids treatment and to develop best in class therapies continues with this collaboration agreement as we work to develop effective approaches to intranasal drug delivery, which is one of the preferred delivery options for targeting the brain. Partnering with Polyrizon and taking advantage of their innovative delivery technology may create mutual opportunities to develop treatments for pain."
Read the full article here.
No. 4 SPRC Potential Catalyst - A JV With MitoCareX Bio Could Send Different Cancers And Diseases Running Scared
SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases
Research to build on studies with support from global experts in the field of small molecule drugs and gene editing
TEL AVIV, Israel, March 31, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced completion of the previously announced joint venture (“JV”) agreement to focus on the discovery and development of potential drugs for cancers and other life-threatening conditions, MitoCareX Bio Ltd., an Israeli corporation (“MitoCareX Bio”) (the “JV Agreement”).
MitoCareX Bio will focus on investigating mitochondrial carriers, transport proteins crucial for cell viability. Because of mitochondrial carriers’ significant role in transporting necessary metabolites for cell functioning across the inner mitochondrial membranes, the Company believes various life-threatening conditions, such as cancers and rare mitochondrial diseases, might be treated by regulating the function of mitochondrial carriers. In humans, the mitochondrial carrier family (Solute Carrier Family 25, SLC25) consists of 53 members and is the largest solute transporter.
Read the full article here.
No. 5 SPRC Potential Catalyst - Explosive Chart History With Multiple Big Runs
As I mentioned in a previous message, SPRC has shown the ability to make huge breakouts in the blink of an eye.
#1. On March 24th, 2022, SPRC opened at $3.95 and ran to a high of $6.99 one day later for a $3.00+ move.
#2. From a $1.95 open on May 12th, SPRC surged to a high of $3.00 and an overall intraday run of 53%.
#3. Most recently on May 24th, SPRC opened at $2.50 and ran to a high of $3.95 for an intraday blast of 58%.
Explosive quick runs.
Could SPRC have another one cooking right around the corner?
SPRC Recap - Multiple Potential Catalysts To Know Now
No. 1 - A Tiny Float Could Allow Major Volatility
No. 2 - Initial Results Come Back Positive For Co-caine Addiction Treatment
No. 3 - A New Collaboration Could Lead To Breakthrough Pain Treatments
No. 4 - A JV With MitoCareX Bio Could Send Different Cancers And Diseases Running Scared
No. 5 - Explosive Chart History With Multiple Big Runs
Coverage is officially initiated on SPRC. When you have time later, do this: